Hi There, my source was a fellow investor who heard that rumors from a year ago were being rekindled. Having looked into it further it seems that the article over a year ago resurfaced. Looking at it I can't see any legs in it. If there is a buyout, which it looks this company is ripe for, it will be GSK or maybe Merck....I am holding here as although Hep B looks good I think the oncology is potentially a lot more lucrative. A big win for any buy out I would think.....original piece from a year ago looks like a seeking alpha article.
Market Data 
Markets 
AI
